BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37340403)

  • 1. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.
    Abu Al Karsaneh O; Al Anber A; ALQudah M; Al-Mustafa S; AlMa'aitah H; Sughayer M
    Diagn Pathol; 2023 Jun; 18(1):75. PubMed ID: 37340403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    Kim EK; Kim KA; Lee CY; Shim HS
    PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
    Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
    J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Genomic Features of
    Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
    JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
    Lim TH; Lim AST; Tien SL; Tan PH
    Ann Diagn Pathol; 2022 Jun; 58():151935. PubMed ID: 35313158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
    Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
    Moktefi A; Pouessel D; Liu J; Sirab N; Maille P; Soyeux P; Bergman CC; Auriault ML; Vordos D; Taille A; Culine S; Allory Y
    Mod Pathol; 2018 Aug; 31(8):1270-1281. PubMed ID: 29467478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
    Zare SY; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
    Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer.
    Xia Q; Zhu Z; Wang J; Situ D; Zhou N; Jang W
    Tumour Biol; 2012 Oct; 33(5):1719-25. PubMed ID: 22736332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 neu expression in head and neck squamous cell cancers and its clinicopathological correlation: Results from an Indian cancer center.
    Vats S; Ganesh MS; Agarwal A
    Indian J Pathol Microbiol; 2018; 61(3):313-318. PubMed ID: 30004046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p95HER2 truncated form in resected non-small cell lung cancer.
    Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
    J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
    Siegfried JM; Lin Y; Diergaarde B; Lin HM; Dacic S; Pennathur A; Weissfeld JL; Romkes M; Nukui T; Stabile LP
    Neoplasia; 2015 Nov; 17(11):817-25. PubMed ID: 26678909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
    Ninomiya K; Hata T; Yoshioka H; Ohashi K; Bessho A; Hosokawa S; Ishikawa N; Yamasaki M; Shibayama T; Aoe K; Kozuki T; Harita S; Ueda Y; Murakami T; Fujimoto N; Yanai H; Toyooka S; Takata M; Hotta K; Kiura K;
    Chest; 2019 Aug; 156(2):357-366. PubMed ID: 31072612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
    PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
    Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
    Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
    Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
    Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
    Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y
    J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.